Chemomab TherapeuticsCMMB
13F holders, Q2 2024 (June 30)15holders +1
3new positions
2sold out
1famous investor
$0.91avg. 13F price*
At the end of Q2 2024, 15 institutions reported holding Chemomab Therapeutics Ltd. (CMMB) in their 13F filings, up 1 from Q1 2024. 3 opened new positions and 2 sold out. The largest holders were Orbimed Advisors LLC ($2.0M), Ikarian Capital, LLC ($196K) and Citadel Advisors ($57K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Chemomab Therapeutics Ltd.
- CUSIP
- 16385C104
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $72K |
| Exits | 2 | $29K |
All 13F filers, Q1 2024 → Q2 2024: 84,121 shares bought and 72,963 shares sold, net +11,158 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 15 holders
| Orbimed Advisors LLC | 0.04% | Reduce 0.0% | 2,241,273 | $2.0M |
| Ikarian Capital, LLC | 0.06% | No change | 213,392 | $196K |
| Citadel Advisors | 0.00% | New | 62,402 | $57K |
| Kestra Private Wealth Services, LLC | 0.00% | No change | 31,241 | $29K |
| Boothbay Fund Management, LLC | 0.00% | No change | 26,529 | $24K |
| Two Sigma Investments, LP | 0.00% | Reduce -39.0% | 24,394 | $22K |
| Rhumbline Advisers | 0.00% | Add +6.7% | 19,877 | $18K |
| Two Sigma Advisers, LP | 0.00% | Reduce -52.1% | 18,100 | $17K |
| XTX Topco Ltd | 0.00% | New | 15,066 | $14K |
| Geode Capital Management, LLC | 0.00% | No change | 11,737 | $11K |
| Morgan Stanley | 0.00% | Add +157.4% | 7,200 | $7K |
| Osaic Holdings, Inc. | 0.00% | New | 1,000 | $912 |
| Moser Wealth Advisors, LLC | 0.00% | No change | 500 | $456 |
| Qube Research & Technologies Ltd | 0.00% | No change | 44 | $40 |
| JPMorgan Chase & Co. | 0.00% | No change | 1 | $1 |
"% of holder's portfolio" is CMMB's weight in each manager's 13F, not the share of Chemomab Therapeutics Ltd. the manager owns.